LA JOLLA, Calif., April 22, 2020 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient?s innate immune system to fight disease, announced today that the United States Patent and Trademark Office (USPTO) has given formal notice of allowance in patent application serial no. 15/268,399, titled ?IN VIVO PRIMING OF NATURAL KILLER CELLS,? which covers a method of treating cancer by administering a proprietary inactivated cellular material preparation and contacting a patient?s own natural killer cells within the body to induce an in vivo response, namely, the priming of NK cells for enhancing innate immunity and the NK cell ability to recognize and kill cancer cells within the patient.
News
INmune Bio Co-Founder and CEO RJ Tesi Presents at Cambridge Healthcare Institute?s 7th Annual Immuno-Oncology Summit
LA JOLLA, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient?s innate immune system to fight disease, today announced that RJ Tesi, M.D., co-found… […]
News
INmune Bio Co-Founder and CEO Presents at 17th Annual Congress of International Drug Discovery Science & Technology 2019
LA JOLLA, Calif., July 25, 2019 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient?s innate immune system to fight disease, today announced that C.J. Barnum, Director o… […]
News
INmune Bio Invited to Speak on Company?s Advancements in Cancer Treatments at the Targeting Innate Immunity Congress and MarketsandMarkets Next Gen Immuno-Oncology Congress
La Jolla, CA., Sept. 17, 2019 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient?s innate immune system to fight disease, today announced that RJ Tesi, M.D., Co-Founder… […]
